Trop-2 drug combo for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have triple-negative breast cancer that is locally advanced or has spread to other parts of the body, and you have had at least 1 but no more than 2 prior chemotherapy treatments for advanced disease
- You have not had immunotherapy or anti-angiogenic drugs (e.g., bevacizumab) before
- You have at least one tumor that can be measured on scans
- You are in generally good health (ECOG performance status 0-2) and your organs are working well enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
This trial tests a combination of two drugs—an antibody-drug conjugate that targets a protein on cancer cells and an immunotherapy that helps your immune system attack the tumor—for people with advanced triple-negative breast cancer that has already been treated. It aims to see if this combo can shrink tumors or slow the disease.
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of two drugs—sacituzumab govitecan and toripalimab—against another combination (toripalimab plus nab-paclitaxel) for people with advanced triple-negative breast cancer that is PD-L1 positive. The goal is to see which combination works better and has fewer side effects.
This phase 2 trial tests two different drug combinations given in an alternating pattern for people with advanced triple-negative breast cancer that is HER2-low. The goal is to see if this approach is safe and effective.
Hear when a new Evaluating the Efficacy of Trop-2 ADC Combination Therapy in Advanced Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.